Carbon Recycling International (CRI) and Dastur Energy Enter Into a Partnership Agreement for Developing CO2 to Methanol Projects in India
15.9.2022 07:30:00 EEST | Business Wire | Press release
Icelandic environmental technology company Carbon Recycling International (CRI) and Dastur Energy Pvt Ltd, the Indian subsidiary of US based Dastur Energy and a part of the Dastur group of companies, have signed an important partnership agreement for marketing, business development, technology licensing, design and engineering of CO2 to Methanol projects based on CRI’s ETL technology in India.
Carbon Recycling International (CRI) has for the past 15 years established a unique position as a pioneer in the utilization of global carbon dioxide emissions. The company's ETL technology is based on the conversion of carbon dioxide released by industry into methanol, which replaces petroleum raw materials and has a muchlower environmental impact.
Dastur is a leading international consulting engineering firm founded in 1955 focusing on the metals, mining, infrastructure and the energy industry. Its headquarters are in Kolkata, India, with offices around the world. Dastur Energy, specializes in clean energy and energy infrastructure projects and is India's leading organization in the field of carbon capture, and industrial decarbonization.
India's methanol sales are growing rapidly and are now around 2.5 million tonnes annually. The size of the market is expected to reach more than 7.5 million tonnes per year within 10 years. The Indian government supports the increased use of methanol as fuel with the aim of reducing air pollution and greenhouse gas emissions and increasing the share of domestic energy sources in the economy.
"Economically viable methods for utilizing carbon dioxide are key to accelerating global efforts to reduce carbon emissions. We see significant opportunities in India for methanol produced sustainably. CRI's ETL technology solution is one of the most advanced in the world today. We are delighted to collaborate with CRI to bring this unique technology to progressive Indian companies in the public and private sectors, who are seeking green methanol as part of their product offering", said Atanu Mukherjee, CEO of Dastur Energy and Dastur.
CRI has two major projects underway based on its ETL technology. The two plants currently under construction in China will each produce more than 100,000 tons of methanol per year,. directly re-using 150,000 metric tons of carbon dioxide annually as raw material .
"A strong partnership between CRI and Dastur makes it possible to accelerate the introduction and deployment of our sustainable technology solutions to a new market where there are great growth opportunities. Environmentally friendly technologies such as the one developed by CRI will play a key role in the essential transformations in industry and energy markets ahead. It will be a pleasure to see Icelandic environmental technology in the Indian market", said Björk Kristjánsdóttir, CEO of CRI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005880/en/
Contact information
Dastur Energy
http://www.dasturenergy.com/
USA: Abhijit Sarkar
+1 512.823.0398
Abhijit.S@dasturenergy.com
India: Saurav Chatterjee
+91 98313 04985
Saurav.Ch@dastur.com
CRI
https://www.carbonrecycling.is/
Iceland: Omar Sigurbjornsson
+354 865 5736
omar@cri.is
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom